H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Viking Therapeutics Analyst Ratings
Viking Therapeutics' VK2735 Gains Buy Rating Amid Pfizer's GLP-1 Drug Halt and Promising Trial Results
Goldman Sachs Maintains Viking Therapeutics(VKTX.US) With Hold Rating, Maintains Target Price $30
Viking Therapeutics Initiated at Neutral by Goldman Sachs
Viking Therapeutics Analyst Ratings
Goldman Sachs Initiates Viking Therapeutics(VKTX.US) With Hold Rating, Announces Target Price $30
Cautious Hold Rating for Viking Therapeutics Amid Competitive Obesity Market Challenges
Analysts Conflicted on These Healthcare Names: Zentalis Pharmaceuticals (ZNTL) and Viking Therapeutics (VKTX)
William Blair Maintains Viking Therapeutics(VKTX.US) With Buy Rating
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Viking Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Electrocore (ECOR), Viking Therapeutics (VKTX) and Lyell Immunopharma (LYEL)
Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $110
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $96 to $105
Viking Therapeutics Secures Strategic Manufacturing Agreement With CordenPharma, Boosting Growth Potential and Earning Buy Rating
Viking Therapeutics Analyst Ratings
B.Riley Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $96
Analysts' Top Healthcare Picks: Editas Medicine (EDIT), Viking Therapeutics (VKTX)